{
    "score": [
        0.6153846153846154
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "nationwide fund advisors has $ 1.77 million position in intersect ent inc ."
    ],
    "id": "401717.train",
    "article": [
        "nationwide fund advisors increased its holdings in intersect ent inc by 4.4 % during the 3rd quarter , according to the company in its most recent disclosure with the securities & exchange commission . the fund owned 56,901 shares of the medical equipment provider 's stock after purchasing an additional 2,377 shares during the quarter . nationwide fund advisors owned approximately 0.19 % of intersect ent worth $ 1,772,000 at the end of the most recent reporting period . other institutional investors have also modified their holdings of the company . teachers advisors llc grew its stake in shares of intersect ent by 7.5 % in the second quarter . ",
        "teachers advisors llc now owns 66,492 shares of the medical equipment provider 's stock worth $ 1,858,000 after purchasing an additional 4,634 shares during the last quarter . verition fund management llc bought a new stake in intersect ent during the second quarter valued at $ 331,000 . swiss national bank boosted its position in intersect ent by 23.7 % during the second quarter . swiss national bank now owns 42,800 shares of the medical equipment provider 's stock valued at $ 1,196,000 after acquiring an additional 8,200 shares during the last quarter . bank of new york mellon corp boosted its position in intersect ent by 23.0 % during the second quarter . ",
        "bank of new york mellon corp now owns 185,117 shares of the medical equipment provider 's stock valued at $ 5,174,000 after acquiring an additional 34,577 shares during the last quarter . finally , tiaa cref investment management llc boosted its position in intersect ent by 3.7 % during the second quarter . tiaa cref investment management llc now owns 139,377 shares of the medical equipment provider 's stock valued at $ 3,896,000 after acquiring an additional 5,033 shares during the last quarter . 86.31 % of the stock is currently owned by institutional investors . intersect ent inc opened at $ 32.85 on friday . ",
        "intersect ent inc has a fifty-two week low of $ 11.40 and a fifty-two week high of $ 34.40 . intersect ent last announced its quarterly earnings data on thursday , november 2nd . the medical equipment provider reported earnings per share for the quarter , beating the consensus estimate of by $ 0.05 . intersect ent had a negative net margin of 19.81 % and a negative return on equity of 15.96 % . the firm had revenue of $ 22.31 million for the quarter , compared to analyst estimates of $ 21.53 million . during the same quarter in the prior year , the business earned earnings per share . ",
        "the business 's quarterly revenue was up 20.8 % compared to the same quarter last year . sell-side analysts forecast that intersect ent inc will post -0.63 earnings per share for the current year . in related news , director frederic h. moll sold 6,700 shares of the company 's stock in a transaction dated thursday , november 16th . the shares were sold at an average price of $ 28.77 , for a total value of $ 192,759.00 . following the sale , the director now owns 247,124 shares in the company , valued at approximately $ 7,109,757.48 . ",
        "the transaction was disclosed in a document filed with the securities & exchange commission , which is available at this hyperlink . also , cfo jeryl l. hilleman sold 12,833 shares of the company 's stock in a transaction dated wednesday , october 4th . the stock was sold at an average price of $ 29.96 , for a total transaction of $ 384,476.68 . the disclosure for this sale can be found here . insiders have sold 140,523 shares of company stock worth $ 4,233,141 in the last quarter . company insiders own 13.70 % of the company 's stock . ",
        "a number of brokerages have commented on xent . canaccord genuity reaffirmed a `` buy '' rating and set a $ 36.00 price target on shares of intersect ent in a research report on monday , december 11th . bidaskclub cut shares of intersect ent from a `` hold '' rating to a `` sell '' rating in a research report on wednesday . bank of america upped their price target on shares of intersect ent from $ 33.00 to $ 40.00 and gave the company a `` buy '' rating in a research report on monday , september 11th . ",
        "guggenheim reaffirmed a `` buy '' rating and set a $ 41.00 price target on shares of intersect ent in a research report on friday , december 15th . finally , zacks investment research raised shares of intersect ent from a `` hold '' rating to a `` buy '' rating and set a $ 33.00 price target on the stock in a research report on thursday , october 5th . one analyst has rated the stock with a sell rating , four have given a hold rating and seven have assigned a buy rating to the company 's stock . ",
        "the stock currently has an average rating of `` buy '' and a consensus target price of $ 33.38 . illegal activity warning : this news story was first reported by watch list news and is the sole property of of watch list news . if you are accessing this news story on another domain , it was stolen and reposted in violation of u. s. and international copyright and trademark law . the legal version of this news story can be accessed at ent company profileintersect ent , inc is a commercial-stage drug-device company . the company develops drugs for patients with ear , nose and throat conditions . ",
        "the company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents . this targeted drug delivery technology is designed to allow ent physicians to manage patient care .   "
    ]
}